| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 27.80 | 18.6% |
| Total Income | 27.80 | 18.6% |
| Expenditure | 25.15 | 1.4% |
| PBT | — | |
| Net Profit | 0.46 | 113.0% |
| OPM | 9.52% | 18.40pp |
| NPM | 1.65% | 16.70pp |
| EPS | 0.05 | 112.2% |
Sanara MedTech Reports Q1 2026: Revenue Up 19%, EPS $0.04
12 May 2026 · 12 May, 2:56 am
Summary
Sanara MedTech Inc. reported a 19% increase in net revenue for the first quarter of 2026, reaching $27.8 million compared to $23.4 million in the same period last year. The company achieved net profitability from continuing operations at $0.04 per diluted share, a significant improvement from the net loss of $0.07 per diluted share in the first quarter of 2025. Gross profit also increased to $25.9 million, representing 93% of net revenue. Looking ahead, Sanara MedTech reaffirms its full-year revenue guidance, expecting net revenue to range from $116 million to $121 million, reflecting growth of 13% to 17%.
Key Highlights
- 1
Net revenue increased by 19% to $27.8 million in the first quarter of 2026, compared to $23.4 million in the first quarter of 2025.
- 2
Gross profit reached $25.9 million, representing 93% of net revenue, compared to $21.6 million, or 92% of net revenue, in the first quarter of 2025.
- 3
Operating income was $2.6 million, compared to $0.8 million in the first quarter of 2025.
- 4
Net income from continuing operations was $0.4 million, or $0.04 per diluted share, compared to a net loss of $0.6 million, or $0.07 per diluted share, in the first quarter of 2025.
- 5
Adjusted EBITDA increased by 58% to $4.3 million, compared to $2.7 million in the first quarter of 2025.
- 6
The company reaffirms full year 2026 net revenue guidance to range from $116 million to $121 million, representing growth of approximately 13% to 17%.
Management Comments
Seth Yon
The first quarter of 2026 is the first full quarter in which the Company was entirely focused on the surgical market, and the results reflected strong execution. We delivered net revenue growth of 19% and gross margin improvement, and achieved GAAP net profitability, a reflection of the strength of our sharpened focus and enhanced financial model. We’re particularly encouraged by these results given that the first quarter is historically our slowest sales period of the year and was also impacted by a three-day shipping interruption in January due to a weather-related shut down. “During the end of 2025 and continuing into 2026, we began strengthening our sales team in an effort to support enhanced net revenue growth and our heightened focus on the surgical setting, expanding the sales team to reach a total of 43 reps,” Mr. Yon stated. “Additionally, we experienced meaningful growth in our surgeon users in the first quarter of 2026 as compared to the first quarter of 2025, and, as of quarter end, our products were contracted or approved to be sold in over 4,000 hospitals and ambulatory surgery centers throughout the United States, our products were sold in over 1,400 facilities throughout the United States, and we had agreements with more than 450 distributors. “Looking ahead, we believe we are well positioned with our strengthened sales team and refined, pure play focus on the surgical operating setting to drive enhanced results. From a capital allocation perspective, this means tightening our scope and strategically investing in R&D to grow our pipeline and introduce new products to the market. With our visibility today, we remain confident in our full-year guidance of 13% to 17% net revenue growth,” Mr. Yon concluded.
Informational and educational content only. Not investment advice.